A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Leukemia

Volumn 31, Issue 12, 2017, Pages 2726-2731

  Passamonti, F ^a   Giorgino, T ^b   Mora, B ^a   Guglielmelli, P ^c   Rumi, E ^d   Maffioli, M ^a   Rambaldi, A ^e   Caramella, M ^f   Komrokji, R ^g   Gotlib, J ^h   Kiladjian, J J ⁱ   Cervantes, F ^j   Devos, T ^k   Palandri, F ^l   De Stefano, V ^m   Ruggeri, M ⁿ   Silver, R T ^o   Benevolo, G ^p   Albano, F ^q   Caramazza, D ^a   Merli, M ^a   Pietra, D ^d   Casalone, R ^r   Rotunno, G ^c   Barbui, T ^s   Cazzola, M ^d   Vannucchi, A M ^c   more..

^a UNIVERSITY OF INSUBRIA   (Italy)

^b CNR   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j UNIVERSITY OF BARCELONA   (Spain)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m CATHOLIC UNIVERSITY   (Italy)

ⁿ SAN BORTOLO HOSPITAL   (Italy)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^q UNIVERSITY OF BARI   (Italy)

^r OSPEDALE DI CIRCOLO   (Italy)

^s Research Foundation AO Papa Giovanni XXIII   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSESSMENT; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; POLYCYTHEMIA VERA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; SYMPTOM; THROMBOCYTE COUNT; THROMBOCYTHEMIA; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; MYELOID METAPLASIA; RISK FACTOR; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 85026405393     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.169     Document Type: Article

References (38)

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405.
2. Passamonti F, Maffioli M. Update from the latest WHO classification of MPNs: a user's manual. Hematol Am Soc Hematol Educ Program 2016; 2016: 534–542.
3. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437–438.
4. Passamonti F, Rumi E, Arcaini L, Castagnola C, Lunghi M, Bernasconi P et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer 2005; 104: 1032–1036.
5. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008; 111: 3383–3387.
6. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901.
7. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392–397.
8. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708.
9. Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica 2014; 99: e55–e57.
10. Gowin K, Coakley M, Kosiorek H, Mesa R. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/ essential thrombocytosis myelofibrosis. Haematologica 2016; 101: e405–e406.
11. Chen M, Xu ZF, Xu JQ, Li B, Zhang PH, Qin TJ et al. Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Zhonghua Xue Ye Xue Za Zhi 2016; 37: 876–880.
12. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861–1869.
13. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472–1477.
14. Wassie E, Finke C, Gangat N, Lasho TL, Pardanani A, Hanson CA et al. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and pheno-typic correlates in 826 patients. Br J Haematol 2015; 169: 71–76.
15. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014; 124: 1062–1069.
16. Rozovski U, Verstovsek S, Manshouri T, Dembitz V, Bozinovic K, Newberry K et al. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica 2017; 102: 79–84.
17. Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M et al. Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia 2016.
18. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.
19. Pavlou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M et al. How to develop a more accurate risk prediction model when there are few events. BMJ 2015; 351: h3868.
20. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010; 33: 1–22.
21. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–526.
22. Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F et al. Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group. Am J Hematol 2016; 91: 681–686.
23. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761–770.
24. Mesa RA, Passamonti F. Individualizing care for patients with myeloproliferative neoplasms: integrating genetics, evolving therapies, and patient-specific disease burden. Am Soc Clin Oncol Educ Book 2016; 35: e324–e335.
25. Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014; 123: 1833–1835.
26. Barosi G, Zhang MJ, Peter Gale R. Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? Leukemia 2014; 28: 2267–2270.
27. Passamonti F, Vannucchi AM, Cervantes F, Harrison C, Morra E, Kantarjian H et al. Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia 2015; 29: 739–740.
28. Cervantes F, Pereira A. Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood 2017; 129: 832–837.
29. Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 2015; 125: 3347–3350.
30. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013; 27: 1322–1327.
31. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.
32. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787–798.
33. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 2015; 1: 643–651.
34. Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia 2017; 31: 896–902.
35. Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhauser M et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012; 157: 75–85.
36. Marty C, Lacout C, Droin N, Le Couedic JP, Ribrag V, Solary E et al. A role for reactive oxygen species in JAK2(V617F) myeloproliferative neoplasm progression. Leukemia 2013; 27: 2187–2195.
37. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Age-related clonal hematopoiesis associated with adverse outcomes. New Engl J Med 2014; 371: 2488–2498.
38. Vainchenker W, Constantinescu SN, Plo I. Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Res 2016; 5: F1000.